Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population

Supportive Care in Cancer

Volumn 19, Issue 6, 2011, Pages 843-851

  Haiderali, Amin ^a   Menditto, Laura ^a   Good, Margaret ^b   Teitelbaum, April ^c   Wegner, Jessica ^b  

^a GLAXOSMITHKLINE   (United States)

^b Health Economics and Outcomes Research   (United States)

^c i3 Global   (Canada)

Author keywords

CINV; Functional Living Index Emesis (FLIE); Medication costs

Indexed keywords

ALPRAZOLAM; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOXORUBICIN; DRONABINOL; EPIRUBICIN; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PREDNISONE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROMETHAZINE;

ADULT; AGED; ARTICLE; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; FUNCTIONAL LIVING INDEX EMESIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; UNITED STATES; WORK PRODUCTIVITY AND ASSESSMENT INVENTORY NAUSEA AND VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; ECONOMICS; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEOPLASM; PSYCHOLOGICAL ASPECT; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; UNITED STATES; VOMITING;

EID: 80051640896     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0915-9     Document Type: Article

References (14)

1. Ballatori E, Roila F, Ruggeri B, Porrozzi S et al (2007) The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 15:31-38 (Pubitemid 46088311)
2. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M et al (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478 (Pubitemid 46630986)
3. Cohen L, de Moor CA, Eisenberg P, Ming EE et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503 (Pubitemid 46570778)
4. Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289-1294 (Pubitemid 46202287)
5. Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment-how are we doing? Support Oncol 2(Suppl 1):1-10
6. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-2494
7. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526-536 (Pubitemid 38444561)
8. Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143-1150 (Pubitemid 350007026)
9. Lachaine J, Yelle L, Kaizer L, Dufour A et al (2005) Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2:181-187
10. Naeim A, Dy SM, Lorenz KA, Sanati H et al (2008) Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol 26:3903-3910
11. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117-1122 (Pubitemid 19208867)
12. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353-365
13. Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678-685 (Pubitemid 47106159)
14. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ et al (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278-1285 (Pubitemid 40813003)